A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers

Summary

This study is a first-in-human, multicenter, open-label, nonrandomized, dose-escalation trial to be conducted in 2 sequential parts: * Part A (Dose Escalation) in subjects with advanced malignancies * Part B (Dose Confirmation) in subjects with tumor type(s) to be determined by results of Part A

Timeline

Start

2016-12

Primary completion

2023-12

Completion

2023-12

Drugs

Indications